Presbia

Presbia's mission is to commercialize a surgical solution for presbyopia, the age-related loss of near vision affecting over 1.8 billion people. Its core achievement is the development and CE Mark approval of the Flexivue Microlens, a proprietary corneal inlay implant. The company's strategy has historically focused on securing regulatory approval in key markets like the US and Europe, though recent years have been defined by financial challenges, delisting, and a shift towards restructuring and seeking strategic alternatives to monetize its technology platform.

The Flexivue Microlens is a proprietary, hydrophilic acrylic polymer corneal inlay that uses a small-aperture optical design to increase depth of focus, providing surgical correction for presbyopia through a minimally invasive and potentially reversible procedure.

Faces intense competition from other corneal inlays (Kamra, Raindrop), refractive lens exchange with premium IOLs (Alcon, J&J), laser procedures (PresbyLASIK), and novel pharmacological treatments like Vuity (pilocarpine drops). The commercial track record for corneal inlays has been challenging.